LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Spotlight on Antidiabetic Agents with Cardiovascular or Renoprotective Benefits.

    Madievsky, Ruth

    The Permanente journal

    2018  Volume 22, Page(s) 18–34

    Abstract: Type 2 diabetes mellitus often goes hand in hand with cardiovascular and renal comorbidities. Stroke, myocardial infarction, heart failure, and chronic kidney disease are high-risk complications of type 2 diabetes that contribute to morbidity and ... ...

    Abstract Type 2 diabetes mellitus often goes hand in hand with cardiovascular and renal comorbidities. Stroke, myocardial infarction, heart failure, and chronic kidney disease are high-risk complications of type 2 diabetes that contribute to morbidity and mortality. Recent clinical trials have uncovered evidence that certain antidiabetic agents may confer cardiovascular and/or renal benefits such as reduced cardiovascular and all-cause mortality and reduced need for renal replacement therapy. Two landmark trials in particular, EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes) and LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results), demonstrated the cardioprotective and/or renoprotective effects of empagliflozin and liraglutide, respectively. These trials led to new US Food and Drug Administration indications for empagliflozin and liraglutide as risk reduction for major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Other trials are under way to determine whether these benefits are class effects and what other agents may have a role in risk reduction for cardiovascular and renal disease. This review will summarize the evidence for noninsulin antidiabetic drugs with benefits beyond glycemic control, discuss proposed mechanisms for these effects, and consider their place in therapy.
    MeSH term(s) Cardiovascular Diseases/prevention & control ; Diabetes Mellitus, Type 2/drug therapy ; Humans ; Hypoglycemic Agents/pharmacology ; Hypoglycemic Agents/therapeutic use ; Kidney Diseases/prevention & control
    Chemical Substances Hypoglycemic Agents
    Language English
    Publishing date 2018-09-16
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2062823-7
    ISSN 1552-5775 ; 1552-5767
    ISSN (online) 1552-5775
    ISSN 1552-5767
    DOI 10.7812/TPP/18-034
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Polypharmacy in Nursing Homes.

    Roh, Elaine / Cota, Esteban / Lee, Jason P / Madievsky, Ruth / Eskildsen, Manuel A

    Clinics in geriatric medicine

    2022  Volume 38, Issue 4, Page(s) 653–666

    Abstract: Older adults in the nursing home are at high risk for polypharmacy. This article provides a background of older adults in nursing homes and reviews key steps to address polypharmacy. ...

    Abstract Older adults in the nursing home are at high risk for polypharmacy. This article provides a background of older adults in nursing homes and reviews key steps to address polypharmacy.
    MeSH term(s) Aged ; Humans ; Inappropriate Prescribing ; Nursing Homes ; Polypharmacy
    Language English
    Publishing date 2022-09-11
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1064151-8
    ISSN 1879-8853 ; 0749-0690
    ISSN (online) 1879-8853
    ISSN 0749-0690
    DOI 10.1016/j.cger.2022.05.007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Se 987: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: "Positive Kidney Health": Implementation and design of a pharmacist-led intervention for patients at risk for development or progression of chronic kidney disease.

    Vu, Amanda / Nicholas, Susanne B / Waterman, Amy D / Madievsky, Ruth / Cheng, Felicia / Chon, Janet / Fu, Jeffery Y / Mangione, Carol M / Norris, Keith C / Duru, O Kenrik

    Journal of the American Pharmacists Association : JAPhA

    2022  Volume 63, Issue 2, Page(s) 681–689

    Abstract: Background: Patients with early chronic kidney disease (CKD) or underlying risk factors are often unaware of their kidney test results, common causes of CKD, and ways to lower risk of disease onset/progression.: Objective: To test feasibility of a ... ...

    Abstract Background: Patients with early chronic kidney disease (CKD) or underlying risk factors are often unaware of their kidney test results, common causes of CKD, and ways to lower risk of disease onset/progression.
    Objective: To test feasibility of a pharmacist-led intervention targeting patient education and risk factors in patients with early CKD and those at risk for CKD.
    Practice description: Ambulatory care pharmacists in community-based primary care clinics delivered kidney health education, ordered labs, and recommended medication adjustments.
    Practice innovation: We identified patients with a moderate rate of decline (≥2 mL/min/1.73 m
    Evaluation methods: Outcomes included visit uptake, completion of annual albuminuria screening, and initiation of guideline-directed medications for CKD. Patients were surveyed pre- and post-intervention for kidney health knowledge and perceptions regarding pharmacist-provided information.
    Results: Our sample of 20 participants had a mean eGFR of 59 mL/min/1.73 m
    Conclusion: Barriers to enrollment included fewer participants with multiple risk factors for CKD. The pharmacists were able to engage patients in learning the importance of monitoring and self-management of kidney health. A collaborative practice agreement may enhance a similar intervention that includes initiation of renoprotective medications.
    MeSH term(s) Humans ; Pharmacists ; Albuminuria/prevention & control ; Diabetes Mellitus, Type 2 ; Kidney ; Renal Insufficiency, Chronic/diagnosis ; Renal Insufficiency, Chronic/drug therapy ; Glomerular Filtration Rate ; Disease Progression
    Language English
    Publishing date 2022-11-17
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2118585-2
    ISSN 1544-3450 ; 1544-3191 ; 1086-5802
    ISSN (online) 1544-3450
    ISSN 1544-3191 ; 1086-5802
    DOI 10.1016/j.japh.2022.11.007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1042: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: A randomized controlled trial of a shared decision making intervention for diabetes prevention for women with a history of gestational diabetes mellitus: The Gestational diabetes Risk Attenuation for New Diabetes (GRAND study).

    Madievsky, Ruth / Vu, Amanda / Cheng, Felicia / Chon, Janet / Turk, Norman / Krueger, Ashley / Krong, Jacob / Maranon, Richard / Liu, Sandra / Han, Christina S / Norris, Keith C / Mangione, Carol / Page, Jessica / Thomas, Samuel / Duru, O Kenrik / Moin, Tannaz

    Contemporary clinical trials

    2022  Volume 124, Page(s) 107007

    Abstract: Background: Gestational diabetes mellitus (GDM) is a risk factor for the development of type 2 diabetes. Metformin and lifestyle change through a Diabetes Prevention Program (DPP) are equally effective in preventing diabetes in patients with a GDM ... ...

    Abstract Background: Gestational diabetes mellitus (GDM) is a risk factor for the development of type 2 diabetes. Metformin and lifestyle change through a Diabetes Prevention Program (DPP) are equally effective in preventing diabetes in patients with a GDM history, so women can choose a strategy based on their preferences. This study aims to test whether shared decision making (SDM) can help women with a history of GDM increase adoption of evidence-based strategies and lose weight to lower their risk of incident diabetes in real-world settings.
    Methods: This pragmatic randomized controlled trial (RCT) will test the effectiveness of SDM for diabetes prevention among 310 overweight/obese women with a history of GDM and prediabetes from two large health care systems (n = 155 from UCLA Health and n = 155 from Intermountain Healthcare). The primary outcome is the proportion of participants who lose ≥5% body weight at 12 months. Secondary outcomes include uptake of DPP and/or metformin and other patient-reported outcomes such as patient activation and health-related quality of life. Rates of GDM in a subsequent pregnancy will be an exploratory outcome. A descriptive analysis of costs related to SDM implementation will also be conducted.
    Conclusion: This is the first RCT to examine the effectiveness of SDM on weight loss, lifestyle change and/or metformin use, and other patient-reported outcomes in participants with a GDM history at risk of developing diabetes.
    Trial registration: ClinicalTrials.gov, NCT03766256. Registered on 6 December 2018.
    MeSH term(s) Pregnancy ; Female ; Humans ; Diabetes, Gestational/prevention & control ; Decision Making, Shared ; Diabetes Mellitus, Type 2/prevention & control ; Diabetes Mellitus, Type 2/complications ; Metformin/therapeutic use ; Obesity/complications
    Chemical Substances Metformin (9100L32L2N)
    Language English
    Publishing date 2022-11-13
    Publishing country United States
    Document type Randomized Controlled Trial ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 2182176-8
    ISSN 1559-2030 ; 1551-7144
    ISSN (online) 1559-2030
    ISSN 1551-7144
    DOI 10.1016/j.cct.2022.107007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1581: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top